2024 NaviFUS FUS Symposium Videos Now Available!
In 2024 September 22nd, we hosted the NaviFUS FUS Symposium, featuring groundbreaking advancements in NaviFUS technology and clinical research. Over 240 participants from around the world joined us for sessions on BBB Opening, Neuromodulation, and New Treatments, along with insightful panel discussions.
We’re excited to announce that all session recordings are now available on our Symposium YouTube channel! Don’t miss out on these transformative insights.
Technology System
NaviFUS has two products in development：
NaviFUS® Neuronavigator-guided transcranial focused ultrasound system
NaviFUS® – FUS system that uses ultrasound energy to open the BBB and for neuromodulation; the device has already passed preliminary safety testing.
NAVIRFA® Needle Tracking System
Precise Surgical Tracking Technology
NAVIRFA® – Optical 3D surgical guidance kit and software that can accurately visualize the spatial position of surgical needles in vivo through special imaging algorithms.
Partners & Investors
We are supported by great venture capital and healthcare investors, and we partner with international distributors, physicians, medical institutions, academic researchers, and patient advocacy groups around the world.
OUR PARTNERSHIPSINVESTOR RELATIONS
NaviFUS Latest News
See what we’ve been up to.
NaviFUS Presents Promising Stroke Rehabilitation Data at AOCCN 2025
Taipei, Taiwan – November 25, 2025 – At the 8th Asian–Oceanian Congress of Clinical Neurophysiology (AOCCN 2025) in Taipei, NaviFUS Corp. (6872) announced encouraging early clinical data showing that its neuronavigation-guided focused ultrasound (FUS) system is expanding beyond epilepsy into the field of stroke rehabilitation.
Read more
Genovate and NaviFUS Report Positive Safety Data from Australian Pilot Study in Drug-Resistant Epilepsy
Genovate Biotechnology and NaviFUS Corporation have completed the first cohort of an investigator-initiated pilot study at Alfred Hospital in Australia, using the NaviFUS neuronavigation-guided focused ultrasound system in patients with drug-resistant epilepsy (DRE).
An independent Safety Monitoring Committee confirmed a favorable safety profile with no major safety concerns and recommended moving to the next cohort with additional treatment sessions.
Early results are encouraging, with most participants showing fewer seizure days and lower seizure frequency, including some with >80% reduction from baseline.
NaviFUS Reports Breakthrough in U.S. Epilepsy Trial, Strengthens Global Footprint
NaviFUS Corps. (6872) announced that the U.S. clinical trial of its NaviFUS® focused ultrasound system for drug-resistant epilepsy (DRE), led by Stanford University successfully completed treatment of its first patient at the middle of Aug. The trial is expected to finish enrollment of all six participants in the first half of next year.
Read moreJoin Our Clinical Trials
NaviFUS is now enrolling participants for a new, non-invasive treatment using focused ultrasound for drug-resistant epilepsy and brain tumors.
No surgery. New hope.
Contact NaviFUS
Thank you for your interest in NaviFUS.
Feel free to contact us with any questions regarding collaboration.